Update 2018 Journal Articles

abstract

• Abstract There are recent advances, namely, a standardized method for reporting therapy response (Hopkins criteria), a multicenter prospective cohort study with excellent negative predictive value of 18F-FDG PET/CT for N0 clinical neck, a phase III multicenter randomized controlled study establishing the value of a negative posttherapy 18F-FDG PET/CT for patient management, a phase II randomized controlled study demonstrating radiation dose reduction strategies for human papilloma virus–related disease, and Food and Drug Administration approval of nivolumab for treatment of recurrent head and neck squamous cell carcinoma.

authors

• Sanli, Yasemin
• Zukotynski, Katherine
• Mittra, Erik
• Chen, Delphine L
• Nadel, Helen
• Niederkohr, Ryan D
• Subramaniam, Rathan M

status

• published 

publication date

• December 2018

has subject area

• 1103 Clinical Sciences (FoR)
• Evaluation Studies as Topic (MeSH)
• Fluorodeoxyglucose F18 (MeSH)
• Head and Neck Neoplasms (MeSH)
• Humans (MeSH)
• Magnetic Resonance Imaging (MeSH)
• Multimodal Imaging (MeSH)
• Nuclear Medicine & Medical Imaging (Science Metrix)
• Positron Emission Tomography Computed Tomography (MeSH)
• Radiopharmaceuticals (MeSH)
• Randomized Controlled Trials as Topic (MeSH)
• Squamous Cell Carcinoma of Head and Neck (MeSH)

published in

• Clinical Nuclear Medicine  Journal

keywords

• Evaluation Studies as Topic
• Fluorodeoxyglucose F18
• Head and Neck Neoplasms
• Humans
• Magnetic Resonance Imaging
• Multimodal Imaging
• Positron Emission Tomography Computed Tomography
• Radiopharmaceuticals
• Randomized Controlled Trials as Topic
• Squamous Cell Carcinoma of Head and Neck

Digital Object Identifier (DOI)

• 10.1097/rlu.0000000000002247

PubMed ID

• 30394934

start page

• e439

end page

• e452

volume

• 43

issue

• 12